Association between computed tomographic features and kirsten rat sarcoma viral oncogene mutations in patients with stage i lung adenocarcinoma and their prognostic value

Clinical Lung Cancer

Volumn 17, Issue 4, 2016, Pages 271-278

  Wang, Hua ^a,b   Schabath, Matthew B ^b   Liu, Ying ^a,b   Stringfield, Olya ^b   Balagurunathan, Yoganand ^b   Heine, John J ^b   Eschrich, Steven A ^b   Ye, Zhaoxiang ^a   Gillies, Robert J ^b  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Computed tomography; Imaging; KRAS; Lung neoplasms; Prognosis

Indexed keywords

CONTRAST MEDIUM; K RAS PROTEIN; KRAS PROTEIN, HUMAN; PROTEIN P21;

ADULT; AGED; ARTICLE; BRONCHOGRAPHY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURGERY; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; FEMALE; FISHER EXACT TEST; GENE MUTATION; HAZARD RATIO; HUMAN; KAPLAN MEIER METHOD; LOG RANK TEST; LOGISTIC REGRESSION ANALYSIS; LUNG ADENOCARCINOMA; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; ONCOGENE; OVERALL SURVIVAL; PLEURA; PREDICTIVE VALUE; PREVALENCE; PROPORTIONAL HAZARDS MODEL; STUDENT T TEST; SURVIVAL RATE; WILD TYPE; ADENOCARCINOMA; CANCER STAGING; DIAGNOSTIC IMAGING; GENETICS; LUNG TUMOR; MORTALITY; MUTATION; PROGNOSIS; SURVIVAL ANALYSIS; VERY ELDERLY; X-RAY COMPUTED TOMOGRAPHY;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTO-ONCOGENE PROTEINS P21(RAS); SURVIVAL ANALYSIS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84975769742     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2015.11.002     Document Type: Article

References (40)

1. S. Rodenhuis, M.L. van de Wetering, W.J. Mooi, S.G. Evers, N. van Zandwijk, and J.L. Bos Mutational activation of the K-ras oncogene: a possible pathogenetic factor in adenocarcinoma of the lung N Engl J Med 317 1987 929 935
2. V. Ludovini, F. Bianconi, L. Pistola, and et al. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer J Thorac Oncol 6 2011 707 715
3. W. Pao, T.Y. Wang, G.J. Riely, and et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib PLoS Med 2 2005 e17
4. Y. Loriot, P. Mordant, E. Deutsch, K.A. Olaussen, and J.C. Soria Are RAS mutations predictive markers of resistance to standard chemotherapy? Nat Rev Clin Oncol 6 2009 528 534
5. A.D. Campos-Parra, C. Zuloaga, M.E. Manriquez, and et al. KRAS mutation as the biomarker of response to chemotherapy and EGFR-TKIs in patients with advanced non-small cell lung cancer: clues for its potential use in second-line therapy decision making Am J Clin Oncol 38 2015 33 40
6. D. Meng, M. Yuan, X. Li, and et al. Prognostic value of K-RAS mutations in patients with non-small cell lung cancer: a systematic review with meta-analysis Lung Cancer 81 2013 1 10
7. T. Woo, K. Okudela, T. Yazawa, and et al. Prognostic value of KRAS mutations and Ki-67 expression in stage I lung adenocarcinomas Lung Cancer 65 2009 355 362
8. T. Aoki, Y. Tomoda, H. Watanabe, and et al. Peripheral lung adenocarcinoma: correlation of thin-section CT findings with histologic prognostic factors and survival Radiology 220 2001 803 809
9. S. Takashima, Y. Maruyama, M. Hasegawa, and et al. Prognostic significance of high-resolution CT findings in small peripheral adenocarcinoma of the lung: a retrospective study on 64 patients Lung Cancer 36 2002 289 295
10. S. Takashima, Y. Maruyama, M. Hasegawa, A. Saito, M. Haniuda, and M. Kadoya High-resolution CT features: prognostic significance in peripheral lung adenocarcinoma with bronchioloalveolar carcinoma components Respiration 70 2003 36 42
11. H. Wang, M.B. Schabath, Y. Liu, and et al. Semiquantitative computed tomography characteristics for lung adenocarcinoma and their association with lung cancer survival Clin Lung Cancer 16 2015 e141 e163
12. M. Sugano, K. Shimizu, T. Nakano, and et al. Correlation between computed tomography findings and epidermal growth factor receptor and KRAS gene mutations in patients with pulmonary adenocarcinoma Oncol Rep 26 2011 1205 1211
13. C. Glynn, M.F. Zakowski, and M.S. Ginsberg Are there imaging characteristics associated with epidermal growth factor receptor and KRAS mutations in patients with adenocarcinoma of the lung with bronchioloalveolar features? J Thorac Oncol 5 2010 344 348
14. O. Gevaert, J. Xu, C.D. Hoang, and et al. Non-small cell lung cancer: identifying prognostic imaging biomarkers by leveraging public gene expression microarray data - methods and preliminary results Radiology 264 2012 387 396
15. M.L. Graber The incidence of diagnostic error in medicine BMJ Qual Saf 22 2013 ii21 ii27
16. G.S. Kulkarni, R. Al-Azab, G. Lockwood, and et al. Evidence for a biopsy derived grade artifact among larger prostate glands J Urol 175 2006 505 509
17. T.A. Yap, M. Gerlinger, P.A. Futreal, L. Pusztai, and C. Swanton Intratumor heterogeneity: seeing the wood for the trees Sci Transl Med 4 2012 127ps110
18. S. Querings, J. Altmüller, S. Ansén, and et al. Benchmarking of mutation diagnostics in clinical lung cancer specimens PLoS One 6 2011 e19601
19. D.A. Fenstermacher, R.M. Wenham, D.E. Rollison, and W.S. Dalton Implementing personalized medicine in a cancer center Cancer J 17 2011 528 536
20. L.D. Wood, D.W. Parsons, S. Jones, and et al. The genomic landscapes of human breast and colorectal cancers Science 318 2007 1108 1113
21. C.V. Zwirewich, S. Vedal, R.R. Miller, and N.L. Muller Solitary pulmonary nodule: high-resolution CT and radiologic-pathologic correlation Radiology 179 1991 469 476
22. H.J. Lee, J.M. Goo, C.H. Lee, and et al. Predictive CT findings of malignancy in ground-glass nodules on thin-section chest CT: the effects on radiologist performance Eur Radiol 19 2009 552 560
23. D.M. Hansell, A.A. Bankier, H. MacMahon, T.C. McLoud, N.L. Muller, and J. Remy Fleischner Society: glossary of terms for thoracic imaging Radiology 246 2008 697 722
24. T. Nakazono, Y. Sakao, K. Yamaguchi, S. Imai, H. Kumazoe, and S. Kudo Subtypes of peripheral adenocarcinoma of the lung: differentiation by thin-section CT Eur Radiol 15 2005 1563 1568
25. K. Suda, K. Tomizawa, and T. Mitsudomi Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation Cancer Metastasis Rev 29 2010 49 60
26. M. Mounawar, A. Mukeria, F. Le Calvez, and et al. Patterns of EGFR, HER2, TP53, and KRAS mutations of p14arf expression in non-small cell lung cancers in relation to smoking history Cancer Res 67 2007 5667 5672
27. I.Y. Tam, L.P. Chung, W.S. Suen, and et al. Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features Clin Cancer Res 12 2006 1647 1653
28. G.J. Riely, M.G. Kris, D. Rosenbaum, and et al. Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma Clin Cancer Res 14 2008 5731 5734
29. J.L. Marks, S. Broderick, Q. Zhou, and et al. Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma J Thorac Oncol 3 2008 111 116
30. S. Rodenhuis, and R.J. Slebos The ras oncogenes in human lung cancer Am Rev Respir Dis 142 1990 S27 S30
31. S. Dogan, R. Shen, D.C. Ang, and et al. Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers Clin Cancer Res 18 2012 6169 6177
32. K. Raparia, C. Villa, R. Raj, and P.T. Cagle Peripheral lung adenocarcinomas with KRAS mutations are more likely to invade visceral pleura Arch Pathol Lab Med 139 2015 189 193
33. J.D. Marotti, M.C. Schwab, N.J. McNulty, and et al. Cytomorphologic features of advanced lung adenocarcinomas tested for EGFR and KRAS mutations: a retrospective review of 50 cases Diagn Cytopathol 41 2013 15 21
34. N. Rekhtman, D.C. Ang, G.J. Riely, M. Ladanyi, and A.L. Moreira KRAS mutations are associated with solid growth pattern and tumor-infiltrating leukocytes in lung adenocarcinoma Mod Pathol 26 2013 1307 1319
35. Y.L. Chang, M.W. Lin, J.Y. Shih, C.T. Wu, and Y.C. Lee The significance of visceral pleural surface invasion in 321 cases of non-small cell lung cancers with pleural retraction Ann Surg Oncol 19 2012 3057 3064
36. J.M. Siegfried, A.T. Gillespie, R. Mera, and et al. Prognostic value of specific KRAS mutations in lung adenocarcinomas Cancer Epidemiol Biomarkers Prev 6 1997 841 847
37. C. Lu, J.C. Soria, X. Tang, and et al. Prognostic factors in resected stage I non-small-cell lung cancer: a multivariate analysis of six molecular markers J Clin Oncol 22 2004 4575 4583
38. N. Vasan, J.L. Boyer, and R.S. Herbst A RAS renaissance: emerging targeted therapies for KRAS-mutated non-small cell lung cancer Clin Cancer Res 20 2014 3921 3930
39. J.P. O'Connor, C.J. Rose, J.C. Waterton, R.A. Carano, G.J. Parker, and A. Jackson Imaging intratumor heterogeneity: role in therapy response, resistance, and clinical outcome Clin Cancer Res 21 2015 249 257
40. Gillies RJ, Kinahan PE, Hricak H, Radiomics: images are more than pictures, they are data [e-pub ahead of print]. Radiology. http://dx.doi.org/10.1148/radiol.2015151169.